GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Strides Pharma Science Ltd (BOM:532531) » Definitions » Price-to-Owner-Earnings

Strides Pharma Science (BOM:532531) Price-to-Owner-Earnings : (As of May. 31, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Strides Pharma Science Price-to-Owner-Earnings?

As of today (2025-05-31), Strides Pharma Science's share price is ₹811.25. Strides Pharma Science does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Strides Pharma Science's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Strides Pharma Science was 9.37. The lowest was 4.68. And the median was 5.56.


BOM:532531's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 25.25
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-31), Strides Pharma Science's share price is ₹811.25. Strides Pharma Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹29.32. Therefore, Strides Pharma Science's PE Ratio (TTM) for today is 27.67.

As of today (2025-05-31), Strides Pharma Science's share price is ₹811.25. Strides Pharma Science's EPS without NRI for the trailing twelve months (TTM) ended in was ₹28.49. Therefore, Strides Pharma Science's PE Ratio without NRI for today is 28.48.

During the past 13 years, Strides Pharma Science's highest PE Ratio without NRI was 291.29. The lowest was 5.73. And the median was 22.23.


Strides Pharma Science Price-to-Owner-Earnings Historical Data

The historical data trend for Strides Pharma Science's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strides Pharma Science Price-to-Owner-Earnings Chart

Strides Pharma Science Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Strides Pharma Science Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Strides Pharma Science's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strides Pharma Science's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Strides Pharma Science's Price-to-Owner-Earnings falls into.


;
;

Strides Pharma Science Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Strides Pharma Science's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=811.25/-2.18
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Strides Pharma Science  (BOM:532531) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Strides Pharma Science Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Strides Pharma Science's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Strides Pharma Science Business Description

Traded in Other Exchanges
Address
Strides House, Bannerghatta Road, Bilekahalli, Bengaluru, KA, IND, 560 076
Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market plan focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.

Strides Pharma Science Headlines

No Headlines